Part 3: Innovation of Antibiotics and the Dilemma of Access and Excess
The discovery void
Learn about the reasons behind the modest development of new antibiotics.
- Nearly empty pipeline (article)
- Why don’t we simply develop new antibiotics (video 05:45)
- Alternatives to antibiotics (article)
New business models addressing antibiotic resistance
Learn about the need to generate new collaborative business models addressing antibiotic resistance.
- New business models addressing antibiotic resistance (article)
- How can we tackle this rather critical situation (video 05:58)
- Innovation of antibiotics (quiz)
The access and excess dilemma
Learn about the dilemma of access and excess to antibiotics in low- and middle-income countries.
- Securing access while reducing excess (article)
- Access not excess – rational use of antibiotics (video 04:00)
- Who is responsible? (reflection)
- Test your understanding III (study questions)
- Reflection and analysis: the access-excess dilemma (analytical assignment)
- End of part 3 (article)
Downloads
Here, you can download a reference list for the third part of the course:
Further reading
- Nearly empty pipeline
- Why don’t we simply develop new antibiotics?
- Alternatives to antibiotics
- New business models addressing antibiotic resistance
- How can we tackle this rather critical situation?
- Innovation of antibiotics
- Securing access while reducing excess
- Access not excess – rational use of antibiotics
- Who is responsible?
- Test your understanding III
- Reflection and analysis: the access-excess dilemma
- End of part 3